Search Result

Results for "

TyK2-IN-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cytochrome P450 (1) Drug Derivative (1) IFNAR (2) Interleukin Related (2) Isotope-Labeled Compounds (1) JAK (21) Phosphodiesterase (PDE) (2) PROTACs (1) Reference Standards (1) STAT (3)
By Research Areas:	Cancer (5) Inflammation/Immunology (18)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150096

Zasocitinib 1 Publications Verification NDI-034858; TAK-279	JAK	Inflammation/Immunology
Zasocitinib (NDI-034858) is a *TYK2* inhibitor, target *TYK2 JH2* domain with binding constant K_d of <200 pM .

HY-101762

*TyK2-IN-2*	JAK Phosphodiesterase (PDE)	Inflammation/Immunology
TyK2-IN-2 (Compoud 18) is a potent and selective *TYK2* inhibitor with IC₅₀s of 7 nM, 0.1 μM and 0.05 μM for *TYK2 JH2, IL-23* and IFNα, respectively. TyK2-IN-2 also inhibits phosphodiesterase 4 (PDE4) with an IC₅₀ of 62 nM. TyK2-IN-2 can be used for the research of inflammatory and autoimmune diseases .

HY-131968

BMS-986202 1 Publications Verification	JAK Cytochrome P450	Inflammation/Immunology
BMS-986202 is a potent, selective and orally active *Tyk2* inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-126242S

Tyk2-IN-7	JAK IFNAR Interleukin Related	Inflammation/Immunology
Tyk2-IN-7 is an orally active *TYK2* JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits *TYK2/JAK1/JAK2* kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis .

HY-156409

ABBV-712	JAK	Inflammation/Immunology
ABBV-712 is a selective and orally active inhibitor of Tyrosine kinase 2 (TYK2). ABBV-712 has EC₅₀ values of 0.01, 0.19, and 0.17 μM for *TYK2 JH2, TYK2* cells and human whole blood, respectively. ABBV-712 has anti-inflammatory activity and can be used in the research of autoimmune diseases .

HY-111745

Tyk2-IN-5	JAK	Inflammation/Immunology
Tyk2-IN-5 (compound 6) is a potent, selective and orally active tyrosine kinase 2 (Tyk2) inhibitor that acts on the JH2 structural domain. Tyk2-IN-5 shows a K_i value of 0.086 nM for *Tyk2 JH2* and an IC₅₀ value of 25 nM for IFNα. Tyk2-IN-5 efficiently inhibits the production of IFNγ in a pharmacodynamic rat model and is fully efficacious in a rat model of arthritis .

HY-156466

QL-1200186	STAT Interleukin Related IFNAR	Inflammation/Immunology
QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase *TYK2* pseudokinase domain JH2 (IC₅₀=0.06 nM, *TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC₅₀=9.85 nM，TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2* conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE) .

HY-173357

TYD-68	PROTACs JAK STAT	Inflammation/Immunology
TYD-68 is a highly efficient and selective CRBN-recruited *TYK2* PROTAC degrader with a DC₅₀ value of 0.42 nM. TYD-68 significantly inhibits IL-12 and IFN-α-induced STAT4 and STAT1 phosphorylation, thereby blocking *TYK2*-dependent signaling pathways. TYD-68 can be used in the study of psoriasis. (Pink: Target protein ligand (HY-173359); Black: Linker (HY-W007732B); Blue: E3 ligase ligand (HY-14658); E3 ligase ligand + Linker (HY-173358)) .

HY-101762R

TyK2-IN-2 (Standard)	Reference Standards JAK Phosphodiesterase (PDE)	Inflammation/Immunology
TyK2-IN-2 (Standard) is the analytical standard of TyK2-IN-2 (HY-101762). This product is intended for research and analytical applications. TyK2-IN-2 (Compoud 18) is a potent and selective TYK2 inhibitor with IC₅₀s of 7 nM, 0.1 μM and 0.05 μM for TYK2 JH2, IL-23 and IFNα, respectively. TyK2-IN-2 also inhibits phosphodiesterase 4 (PDE4) with an IC₅₀ of 62 nM. TyK2-IN-2 can be used for the research of inflammatory and autoimmune diseases .

HY-144031S

Tyk2-IN-8	Isotope-Labeled Compounds JAK	Inflammation/Immunology
Tyk2-IN-8 (compound 3) is a selective Tyk-2 inhibitor with an IC₅₀ of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC₅₀ of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease .

HY-177130S

Socrodeucitinib	JAK	Inflammation/Immunology
Socrodeucitinib (Compound Example 58) is an orally active and selective tyrosine kinase 2 (TYK2) inhibitor with an IC₅₀ value of 1.41 nM. Socrodeucitinib exerts anti-inflammatory activity by inhibiting TYK2-mediated cytokine signaling pathways and reducing the secretion of inflammatory factors. Socrodeucitinib is promising for research of autoimmune diseases such as psoriasis and inflammatory diseases .

HY-175983

JAK1/TYK2-IN-5	JAK	Cancer
JAK1/TYK2-IN-5 (compound A1) is a *JAK1/TYK2* inhibitor with K_i values of 0.0044 nM, 0.02 nM, 6.9 μM, 0.79 μM, 0.21 μM and 0.55 μM for TYK2 JH2, JAK1 JH2, JAK1 JH1, JAK2 JH1, JAK3 JH1 and TYK2 JH1, respectiverly. JAK1/TYK2-IN-5 inhibts IFNα induced TYK2/JAK1-mediated STAT activation .

HY-143884

JAK2/TYK2-IN-1 1 Publications Verification	JAK	Inflammation/Immunology
JAK2/TYK2-IN-2 is a potent and selective *TYK2* inhibitor with IC₅₀ values of 9 and 157 nM for *TYK2* and JAK2, respectively. JAK2/TYK2-IN-2 has anti-inflammatory activity .

HY-163304

Tyk2-IN-16	JAK	Cancer
Tyk2-IN-16 is a selective and potent *TYK2* inhibitor with an IC₅₀ of <10 nM for TYK2-JH2. Tyk2-IN-16 inhibits pSTAT4 with an IC₅₀ of <10 nM in NK92 cells (WO2023220046A1; compound 184) .

HY-E70874

TYK2(JH2) Recombinant Human Active Protein Kinase	JAK	Cancer
TYK2 is a member of the JAK family of non-receptor tyrosine kinases that act together with signal transducer and activator of transcription (STAT) factors in mediating intracellular signal transduction. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). TYK2(JH2) Recombinant Human Active Protein Kinase is a recombinant TYK2(JH2) protein that can be used to study TYK2(JH2)-related functions .

HY-149892S

TYK2 JH2-IN-1-d3	JAK	Cancer
TYK2?JH2-IN-1-d₃ is the a deuterated, orally active and selective TYK2 inhibitor (compound 4h), targeting to JH2 domain (IC₅₀=0.1 nM) .

HY-163303

Tyk2-IN-15	JAK	Inflammation/Immunology
Tyk2-in-15 (Compound 97) is a selective tyrosine kinase 2 (Tyk2) inhibitor with IC₅₀ value ≤ 10 nM for Tyk2-JH2. Tyk2-IN-15 can be used in the study of inflammatory or autoimmune diseases .

HY-144032

Tyk2-IN-9	JAK	Inflammation/Immunology
Tyk2-IN-9 (Compound 26) is a selective *Tyk-2* inhibitor with IC₅₀s of 0.076 and 1.8 nM for TYK2-JH2 and JAK1-JH2, respectively. Tyk2-IN-9 can be used for the research of inflammatory or autoimmune disease .

HY-144087

TYK2-IN-11	JAK	Inflammation/Immunology
TYK2-IN-11 (Compound 5B) is a selective *Tyk-2* inhibitor with IC₅₀s of 0.016 and 0.31 nM for TYK2-JH2 and JAK1-JH2, respectively. TYK2-IN-11 can be used for the research of inflammatory or autoimmune disease .

HY-173359

*TYK2 ligand 2*	JAK	Inflammation/Immunology
TYK2 ligand 2 is a *TYK2* ligand for TYD-68 (HY-173357). TYD-68 is a highly efficient and selective CRBN-recruited TYK2 PROTAC degrader with a DC₅₀ value of 0.42 nM. TYD-68 can be used in the study of psoriasis .

HY-181278

Deucravacitinib analog 1	Drug Derivative JAK	Inflammation/Immunology Cancer
Deucravacitinib analog 1 (compound 3), Deucravacitinib (HY-117287) derivative, is a *TYK2* allosteric ligand. Deucravacitinib analog 1 binds to the JH2 domain of TYK2. Deucravacitinib analog 1 serves as a starting point for development of TYK2-targeting PROTAC degraders. Deucravacitinib analog 1 can be used for the researches of psoriasis and cancer .

HY-178913

Tyk2-IN-23	JAK STAT	Inflammation/Immunology
Tyk2-IN-23 is a potent, orally active, selective TYK2 inhibitor (IC₅₀ = 18 nM), exhibiting more than > 70-fold selectivity over JAK1/2/3 isoforms. Tyk2-IN-23 potently inhibits p-STAT3 in TYK2-dependent signaling activated by IFN-α and IL-10. Tyk2-IN-23 potently inhibits IFN-α-induced STAT1 phosphorylation in H9 cells. Tyk2-IN-23 can be used for the study of alopecia areata and allergic Rhinitis .

Cat. No.	Product Name	Chemical Structure

HY-131968

BMS-986202 1 Publications Verification
BMS-986202 is a potent, selective and orally active *Tyk2* inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

BMS-986202

1 Publications Verification

BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-126242S

Tyk2-IN-7
Tyk2-IN-7 is an orally active *TYK2* JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits *TYK2/JAK1/JAK2* kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis .

Tyk2-IN-7

Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis .

HY-144031S

Tyk2-IN-8
Tyk2-IN-8 (compound 3) is a selective Tyk-2 inhibitor with an IC₅₀ of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC₅₀ of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease .

HY-177130S

Socrodeucitinib
Socrodeucitinib (Compound Example 58) is an orally active and selective tyrosine kinase 2 (TYK2) inhibitor with an IC₅₀ value of 1.41 nM. Socrodeucitinib exerts anti-inflammatory activity by inhibiting TYK2-mediated cytokine signaling pathways and reducing the secretion of inflammatory factors. Socrodeucitinib is promising for research of autoimmune diseases such as psoriasis and inflammatory diseases .

Socrodeucitinib

Socrodeucitinib (Compound Example 58) is an orally active and selective tyrosine kinase 2 (TYK2) inhibitor with an IC₅₀ value of 1.41 nM. Socrodeucitinib exerts anti-inflammatory activity by inhibiting TYK2-mediated cytokine signaling pathways and reducing the secretion of inflammatory factors. Socrodeucitinib is promising for research of autoimmune diseases such as psoriasis and inflammatory diseases .

HY-149892S

TYK2 JH2-IN-1-d3
TYK2?JH2-IN-1-d₃ is the a deuterated, orally active and selective TYK2 inhibitor (compound 4h), targeting to JH2 domain (IC₅₀=0.1 nM) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.